An Evaluation of Cation–Chloride Cotransporters NKCC1 and KCC2 in Carbamazepine-Resistant Rats
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26104764 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Cecilia Zavala-Tecuapetla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Insurgentes Sur 3877…. Hauptthemen laut MEDLINE: Symporters, Solute Carrier Family 12, Member 2, Carbamazepine, Anticonvulsants. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Approximately one-third of epileptic patients do not respond adequately to drug therapy, leading to the development of drug-resistant epilepsy. Given the established role of dysregulated expression of two cation–chloride cotransporter proteins, NKCC1 and KCC2, in susceptibility to convulsion generation and epilepsy development, the present study evaluates the anticonvulsant potential of bumetanide (BUM, 10 mg/kg, i.p.) and probenecid (PROB, 50 mg/kg, i.p.), the potential of adenosine receptor activation (NECA, 1 mg/kg, i.p.) to modify the anticonvulsant efficacy of BUM, and the changes in NKCC1 and KCC2 protein expression levels in carbamazepine (CBZ)-resistant animals. In the window–pentylenetetrazole (PTZ) kindling model, male Wistar rats that undergo full kindling develop CBZ-resistance. The combination of BUM + PROB appears to have an anticonvulsant effect on CBZ-resistant convulsions, while alterations in the protein levels of the NKCC1 and KCC2 cotransporters are observed in CBZ-resistant animals. Despite the absence of therapeutic efficacy in managing convulsions through adenosine receptor activation (BUM + NECA), the activation of adenosine receptors exhibits the capacity to modulate the levels of the NKCC1 protein in the hippocampus of CBZ-resistant animals. This effect provides the initial evidence for a new therapeutic role of adenosine receptors in regulating the pathological levels of NKCC1 in drug-resistant epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Insurgentes Sur 3877, La Fama, Mexico City 14269, Mexico.
- Medical Research Unit on Neurological Diseases, Specialty Hospital "Dr. Bernardo Sepúlveda", National Medical Center "XXI Century", Mexican Social Security Institute, Av. Cuauhtémoc 330, Doctores, Mexico City 06720, Mex…
ORCID-Profile: Cecilia Zavala-Tecuapetla, Sandra Orozco-Suárez, Angélica Vega-García
Zitieren
APA
Zavala-Tecuapetla, C., Orozco-Suárez, S., Vega-García, A., & Manjarrez-Marmolejo, J. (2025). An Evaluation of Cation–Chloride Cotransporters NKCC1 and KCC2 in Carbamazepine-Resistant Rats. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104764
Vancouver
Zavala-Tecuapetla C, Orozco-Suárez S, Vega-García A, Manjarrez-Marmolejo J. An Evaluation of Cation–Chloride Cotransporters NKCC1 and KCC2 in Carbamazepine-Resistant Rats. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104764
BibTeX
@article{ZavalaTecuapetla2025,
author = {Zavala-Tecuapetla, Cecilia and Orozco-Suárez, Sandra and Vega-García, Angélica and Manjarrez-Marmolejo, Joaquín},
title = {An Evaluation of Cation–Chloride Cotransporters NKCC1 and KCC2 in Carbamazepine-Resistant Rats},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26104764}
}
EUVIMED